~9 spots leftby Aug 2025

Antioxidant Cocktail for Stroke Prevention

WG
Overseen byWilliam G Schrage, PhD
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: University of Wisconsin, Madison
Must not be taking: Cardiovascular medications, NSAIDs
Disqualifiers: Hypertension, Diabetes, Smoking, others
No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests a special mix of vitamins to see how it affects brain blood flow in healthy young adults. Researchers want to know if men and women respond differently to high oxygen levels.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking all current medications, but it does require stopping hormonal birth control at least one month before the first study visit if it's used for contraception only. Cardiovascular medication use is also an exclusion criterion, so you may need to stop those if applicable.

What data supports the effectiveness of the Antioxidant Cocktail treatment for stroke prevention?

Research shows that antioxidants can help reduce brain damage caused by strokes by neutralizing harmful free radicals. Studies on individual antioxidants like resveratrol and lipoic acid have shown they can protect the brain in animal models of stroke, suggesting potential benefits for humans.12345

Is the Antioxidant Cocktail safe for humans?

The research articles provided do not contain specific safety data for the Antioxidant Cocktail in humans. However, they discuss the potential benefits of antioxidants in stroke prevention and treatment, suggesting that antioxidants may have protective effects on the brain.12467

How does the antioxidant cocktail treatment for stroke prevention differ from other treatments?

The antioxidant cocktail for stroke prevention is unique because it combines multiple antioxidants, potentially enhancing neuroprotection by reducing brain damage from free radicals during a stroke. Unlike conventional treatments, this approach uses a combination of ingredients like resveratrol and lipoic acid, which have shown promise in animal models for reducing stroke damage.23489

Research Team

WG

William G Schrage, PhD

Principal Investigator

University of Wisconsin, Madison

Eligibility Criteria

Healthy adults aged 18-40 can join this study on reactive oxygen species and brain blood flow. Excluded are those with high blood pressure, glucose levels, or a history of heart, liver, kidney diseases; smokers; certain medication users; MRI contraindications; women with irregular menstrual cycles or using hormonal birth control (except copper IUDs).

Inclusion Criteria

I am between 18 and 40 years old.

Exclusion Criteria

You are sensitive to NSAIDs (non-steroidal anti-inflammatory drugs).
I am taking medication for my heart condition.
I have been diagnosed with sleep apnea.
See 29 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants undergo CBF testing in MRI under normoxia and hyperoxia conditions with either placebo or antioxidant cocktail

6 months
2 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Antioxidant Cocktail (Other)
  • Placebo (Other)
Trial OverviewThe trial is testing an antioxidant cocktail against a placebo in 30 healthy participants to understand its effect on cerebral blood flow. The study spans over six months with two visits.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Antioxidant CocktailExperimental Treatment1 Intervention
The first dose will be 500 mg vitamin C, 200 IU vitamin E, and 300 mg of alpha lipoic acid 120 minutes before MRI. The second dose will be 500 mg vitamin C, 400 IU vitamin E, and 300 mg of alpha lipoic acid 60 minutes before MRI.
Group II: PlaceboActive Control1 Intervention
Placebo 120 minutes before MRI, followed by another dose of placebo 60 minutes before MRI.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Wisconsin, Madison

Lead Sponsor

Trials
1,249
Recruited
3,255,000+

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Trials
3,987
Recruited
47,860,000+

Findings from Research

In a multicenter, randomized, placebo-controlled study involving 252 acute ischemic stroke patients, edaravone showed a significant improvement in functional outcomes compared to placebo, as measured by the modified Rankin Scale (p = 0.0382).
Edaravone acts as a neuroprotective agent by inhibiting vascular endothelial cell injury and reducing neuronal damage, suggesting its potential as an effective treatment for acute ischemic stroke when administered within 72 hours of onset.
Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters.[2022]
In a study involving 48 acute ischaemic stroke patients, supplementation with antioxidants (800 IU of alpha-tocopherol and 500 mg of vitamin C) within 12 hours of stroke onset significantly increased antioxidant levels and total antioxidant capacity compared to a control group.
The treatment group also showed a significant reduction in plasma malondialdehyde (MDA), indicating less oxidative damage, and lower C-reactive protein (CRP) levels, suggesting a potential anti-inflammatory effect after 14 days of supplementation.
Antioxidant supplementation enhances antioxidant capacity and mitigates oxidative damage following acute ischaemic stroke.Ullegaddi, R., Powers, HJ., Gariballa, SE.[2013]
Antioxidant compounds may offer potential benefits in preventing or treating acute ischemic stroke by reducing brain damage caused by excessive free radicals, as highlighted in various observational studies and clinical trials.
Promising antioxidants such as dehydroascorbic acid, alpha-tocotrienol, and flavonoids have shown effectiveness in animal models, but there are challenges in translating these results to human patients, indicating a need for improved research methodologies.
Dietary antioxidants as potential pharmacological agents for ischemic stroke.Cherubini, A., Ruggiero, C., Morand, C., et al.[2019]

References

Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. [2022]
Antioxidant supplementation enhances antioxidant capacity and mitigates oxidative damage following acute ischaemic stroke. [2013]
3.United Arab Emiratespubmed.ncbi.nlm.nih.gov
Dietary antioxidants as potential pharmacological agents for ischemic stroke. [2019]
Co-administration of resveratrol and lipoic acid, or their synthetic combination, enhances neuroprotection in a rat model of ischemia/reperfusion. [2021]
Is antioxidant and n-3 supplementation able to improve functional status in poststroke patients? Results from the Nutristroke Trial. [2022]
A meta-analysis of prospective cohort studies of flavonoid subclasses and stroke risk. [2022]
Neuroprotective diets for stroke. [2018]
Oxidants, antioxidants, alcohol and stroke. [2021]
Nitrone spin on cerebral ischemia. [2007]